Skip to content

Gross margin at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
86.2%+0.2pp
LQD
Liquidia CorporationLQDA
58.1%-18.7pp
BridgeBio Pharma logo
BridgeBio PharmaBBIO
95.1%-0.2pp
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
86%-0.2pp
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
91.5%-0.6pp
United Therapeutics logo
United TherapeuticsUTHR
86.6%-2.4pp

Other financials

Income statement

See full
Revenue$127.2M+55.6%
Gross profit$125.2M+62.5%
Operating income-$36.9M+13.5%
Net income-$37.1M+10.0%
EPS (diluted)-$0.40+14.9%

Balance sheet

See full
Cash & equivalents$78.4M+26.6%
Total debt$15.6M-82.6%
Total equity$98.7M+201%
Total assets$555.2M+1.2%

Cash flow

See full
Operating cash flow-$40.4M+4.3%
CapEx$140.0K
Free cash flow-$42.5M+28.1%

Valuation

See full
Market cap$5.13B+72.3%

Profitability

See full
Operating margin-10.6%-5.0pp
Net margin-20.3%-9.5pp
FCF margin-133.9%-34.4pp

Returns & leverage

See full
Return on equity-706%-1,302pp
Debt / equity0.2×-2.6×
Current ratio3.1×+1.1×

Where this comes from

Calculated from Travere Therapeutics, Inc.’s reported figures.

Based on trailing twelve months.

The official record: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Travere Therapeutics, Inc.'s gross margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Travere Therapeutics, Inc.'s gross margin?
Travere Therapeutics, Inc. (TVTX) reported gross margin of 98.6% in Q1 2026.
How has Travere Therapeutics, Inc.'s gross margin changed year-over-year?
Travere Therapeutics, Inc.'s gross margin increased by 2.7% year-over-year, from 96% to 98.6%.
What is the long-term trend for Travere Therapeutics, Inc.'s gross margin?
Over 4 years (2020 to 2025), Travere Therapeutics, Inc.'s gross margin has grown at a 0.3% compound annual growth rate (CAGR), from 96.9% to 97.9%.
What does gross margin mean?
Gross profit (revenue minus cost of revenue) as a percentage of revenue, on a trailing-twelve-month basis. Measures how much of each sales dollar survives the direct cost of producing the goods or services sold.